{{Rsnum
|rsid=4436578
|Gene=DRD2
|Chromosome=11
|position=113436043
|Orientation=plus
|GMAF=0.3489
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DRD2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 2.7 | 22.1 | 75.2
| HCB | 23.4 | 42.3 | 34.3
| JPT | 21.2 | 55.8 | 23.0
| YRI | 37.2 | 47.6 | 15.2
| ASW | 31.6 | 52.6 | 15.8
| CHB | 23.4 | 42.3 | 34.3
| CHD | 18.7 | 48.6 | 32.7
| GIH | 10.0 | 45.0 | 45.0
| LWK | 41.3 | 49.5 | 9.2
| MEX | 3.4 | 29.3 | 67.2
| MKK | 41.3 | 40.6 | 18.1
| TSI | 0.0 | 17.6 | 82.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4436578
|Name_s=
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:20375926
|Annotation=Risk or phenotype-associated allele: C Phenotype: Patients homozygous for the rs4436578-C allele were at increased risk of body weight gain as compared with the heterozygotes and those of the rs4436578-TT genotype after atypical antipsychotics treatment Study size: 479 chronic inpatients with schizophrenia Study population/ethnicity: Chinese Significance metric(s): OR = 3.36 (95% confidence interval=1.62 approximately 7.00) Type of association: GN
|Drugs=clozapine; risperidone
|Drug Classes=ANTIPSYCHOTICS
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165292687
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4436578
|overall_frequency_n=82
|overall_frequency_d=124
|overall_frequency=0.66129
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=70
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}